1. Cancer statistics, 2019
2. Novartis. Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah™ (tisagenlecleucel, CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice novartis [Online]; 2017. Available from: https://novartis.gcs-web.com/novartis-receives-fda-approval-for-KymriahTM
3. Institute NC. Tisagenlecleucel (Kymriah) approved to treat some lymphomas; 2018 [cited 2019 Jul 22]. Available from: https://www.cancer.gov/news-events/cancer-currents-blog/2018/tisagenlecleucel-fda-lymphoma
4. Gilead. Kite’s Yescarta™ (Axicabtagene Ciloleucel) becomes first CAR T therapy approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy gilead [Online]; 2017. Available from: http://www.gilead.com/news/press-releases/2017/10/kites-yescarta-axicabtagene-ciloleucel-becomes-first-car-t-therapy-approved-by-the-fda-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-large-bcell-lymphoma-after-two-or-more-lines-of-systemic-therapy
5. Novartis. Novartis receives European commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel) novartis. [Online]; 2018. Available from: https://www.novartis.com/news/media-releases/novartis-receives-european-commission-approval-its-car-t-cell-therapy-kymriah-tisagenlecleucel